Healthcare -
Biotechnology - NASDAQ - US
$ 3.26
-0.614 %
$ 6.45 M
Market Cap
-1.28
P/E
1. INTRINSIC VALUE
FINANCIALS
Balance Sheet
Alaunos Therapeutics, Inc.
| Current Assets | 2.76 M |
| Cash & Short-Term Investments | 1.09 M |
| Receivables | 5 K |
| Other Current Assets | 1.66 M |
| Non-Current Assets | 0 |
| Long-Term Investments | 0 |
| PP&E | 0 |
| Other Non-Current Assets | 0 |
| Current Liabilities | 692 K |
| Accounts Payable | 516 K |
| Short-Term Debt | 0 |
| Other Current Liabilities | 176 K |
| Non-Current Liabilities | 0 |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Alaunos Therapeutics, Inc.
| Revenue | 10 K |
| Cost Of Revenue | 0 |
| Gross Profit | 10 K |
| Operating Expenses | 4.82 M |
| Operating Income | -4.81 M |
| Other Expenses | -133 K |
| Net Income | -4.68 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Alaunos Therapeutics, Inc.
| Net Income | -4.68 M |
| Depreciation & Amortization | 2 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 435 K |
| Change in Working Capital | -729 K |
| Others | -729 K |
| Free Cash Flow | -4.97 M |
Wall Street Analysts Price Targets
Alaunos Therapeutics, Inc.
TCRT has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
TCRT does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Alaunos Therapeutics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
6.02 K USD 1
9-12 MONTHS
0 USD 0
Bought
3.82 K USD 2
0-3 MONTHS
1.38 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering
HOUSTON, June 23, 2025 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) (the “Company”) today announced that it has entered into a definitive agreement with certain investors (the “SPA”) for the purchase and sale of an aggregate of 610,399 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.36 per share (or pre-funded warrant in lieu thereof) in a registered direct offering (the “Offering”) on June 20, 2025 based on the 5-day average Nasdaq official closing price. The aggregate gross proceeds to the Company of this offering are expected to be approximately $2.0 million, before deducting the offering expenses payable by the Company.
globenewswire.com
- 1 month ago
PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies
NEWPORT BEACH, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC (“PMGC Capital”), a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB), today issued a public statement urging Alaunos Therapeutics, Inc. (NASDAQ: TCRT) to accept and act upon the term sheet previously facilitated through a leading Wall Street Bank.
globenewswire.com
- 1 month ago
PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)
NEWPORT BEACH, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC (“PMGC Capital,” “we,” “our,” or “us”), a wholly owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), today announced its planned filing of a Schedule 13D with the U.S. Securities and Exchange Commission disclosing beneficial ownership of common stock in Alaunos Therapeutics, Inc. (Nasdaq: TCRT).
globenewswire.com
- 2 months ago
Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?
Alaunos Therapeutics (NASDAQ: TCRT ) stock is up on Monday despite a lack of news from the clinical-stage oncology-focused cell therapy company. There are no new press releases or filings with the Securities and Exchange Commission (SEC) that explain why the stock is up today.
investorplace.com
- 1 year ago
Why Is Alaunos Therapeutics (TCRT) Stock Up 14% Today?
Alaunos Therapeutics (NASDAQ: TCRT ) stock is heading higher on Tuesday following the release of the clinical-stage oncology-focused cell therapy company's Q3 earnings report. The Alaunos Therapeutics earnings report starts with earnings per share of -4 cents.
investorplace.com
- 1 year ago
Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives
HOUSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced financial results for the third quarter ended September 30, 2023. As previously announced, the Company is exploring strategic alternatives with Cantor Fitzgerald & Co. as its strategic advisor. Alaunos continues to reduce spend and cost-savings measures taken to date are expected to extend its cash runway into the second quarter of 2024.
globenewswire.com
- 1 year ago
Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65%
Due to a lack of funding needs, Alaunos (TCRT) decides to end its only clinical study. The company will instead focus on its hunTR TCR discovery platform and explore broad strategic alternatives.
zacks.com
- 1 year ago
Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives
HOUSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced financial results for the second quarter ended June 30, 2023. The Company also announced a strategic reprioritization to focus on its hunTR ® TCR discovery platform, wind down its TCR-T Phase 1/2 Library trial and explore broad strategic alternatives for the Company. Alaunos is implementing a cost-savings plan that includes a reduction in workforce by approximately 60%.
globenewswire.com
- 1 year ago
Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023
HOUSTON, May 03, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that it will report financial results for the first quarter ended March 31, 2023, on Wednesday, May 10, 2023, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 9:00 a.m. ET to review the financial results and provide a corporate update.
globenewswire.com
- 2 years ago
Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April
HOUSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that company management will be participating in the following upcoming investor conferences.
globenewswire.com
- 2 years ago
Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023
HOUSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2022, on Tuesday, March 7, 2023, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:30 a.m. ET to review the financial results and provide a corporate update.
globenewswire.com
- 2 years ago
Is Alaunos Therapeutics (TCRT) Outperforming Other Medical Stocks This Year?
Here is how Alaunos (TCRT) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.
zacks.com
- 2 years ago
8. Profile
Summary
Alaunos Therapeutics, Inc. TCRT
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 6.45 M
Dividend Yield
0.00%
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
Contact
8030 El Rio Street, Houston, TX, 77054
https://www.alaunos.com
IPO
Date
Aug. 24, 2005
Employees
1
Officers
Ms. Melinda Lackey
Senior Vice President of Legal, Administration & Secretary
Mr. Ferdinand Groenewald
Vice President of Finance
Mr. Dale Curtis Hogue Jr.
Interim Chief Executive Officer & Director